Is Our DNA in Safe Hands? What the Regeneron Acquisition of 23andMe Means for Security and Privacy
When Regeneron announced its $256 million acquisition of 23andMe, most headlines focused on drug discovery potential. But beneath the surface lies a deeper concern: the fate of 15 million genetic profiles. At Sekurno, we unpack the post-acquisition security risks, Regeneron’s breach history, and why compliance alone isn’t enough to protect the world’s most personal data—your DNA.
Sekurno
May 24, 20254 min read
Understanding FDA Regulation and Cybersecurity Guidance for Software-Enabled Medical Devices
Learn how FDA regulation and cybersecurity guidance apply to software-enabled medical devices, from classification and submission to lifecycle risk management
Kristina Romanenko
May 21, 202512 min read
Building a Biotech Threat Model: A Practical Step-by-Step Guide & Example Case Study
Explore a real-world threat modeling example for a genomics platform using MITRE’s playbook, C4 diagrams, and STRIDE. A practical guide for healthtech and biotech security teams
Alex Rozn
May 20, 202517 min read
Why You Shouldn’t Trust “Top 10 Cybersecurity Companies” Lists
Most "Top 10" security lists are marketing fluff. Here’s how vendors game the system, and what smarter buyers should actually look for when choosing a partner.
Demyd Maiornykov
May 3, 20255 min read
HIPAA Compliance Checklist (Self-Assessment Guide)
Simplify HIPAA compliance with our Self-Assessment Guide. Quickly identify gaps, understand key requirements, and take actionable steps to strengthen your data security and meet regulatory standards. Ideal for startups, biotech, healthtech, and healthcare companies.
Kristina Romanenko
May 2, 20256 min read
The 23andMe Breach: Anatomy, Impact, and Lessons for Genomic Security (Deep Dive)
Explore the anatomy of the 23andMe data breach, its impact on genomic privacy, and critical lessons for biotech security. This deep dive reveals how sensitive genetic data was compromised and what organizations must do to strengthen defenses.
Demyd Maiornykov
Apr 7, 202511 min read